BT-11   Click here for help

GtoPdb Ligand ID: 10363

Synonyms: analogue 7 [PMID: 27933891] | BT11 | Example 1 [US9556146B2]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BT-11 is an orally active anti-inflammatory agent that operates as a LANCL2 pathway activator [3]. It is being developed by Landos Biopharma, and is Example 1 as claimed in patent US9556146B2 [1]. The physicochemical properties of BT-11 suggest that it may offer a drug with minimal systemic distribution, and be more suited to local action in the acidic environment of the gut.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 123.76
Molecular weight 528.2
XLogP 3.07
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(c1cccc(n1)c1nc2c([nH]1)cccc2)N1CCN(CC1)C(=O)c1cccc(n1)c1nc2c([nH]1)cccc2
Isomeric SMILES O=C(c1cccc(n1)c1nc2c([nH]1)cccc2)N1CCN(CC1)C(=O)c1cccc(n1)c1nc2c([nH]1)cccc2
InChI InChI=1S/C30H24N8O2/c39-29(25-13-5-11-23(31-25)27-33-19-7-1-2-8-20(19)34-27)37-15-17-38(18-16-37)30(40)26-14-6-12-24(32-26)28-35-21-9-3-4-10-22(21)36-28/h1-14H,15-18H2,(H,33,34)(H,35,36)
1. Bassaganya-Riera J, Barrios AC, Gandour R, Cooper JD, Hontecillas R. (2017)
Lanthionine synthetase C-like 2-based therapeutics.
Patent number: US9556146B2. Assignee: Landos Biopharma Inc.. Priority date: 24/10/2014. Publication date: 31/01/2017.
2. Bissel P, Boes K, Hinckley J, Jortner BS, Magnin-Bissel G, Werre SR, Ehrich M, Carbo A, Philipson C, Hontecillas R et al.. (2016)
Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease.
Int J Toxicol, 35 (5): 521-9. [PMID:27230993]
3. Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J. (2016)
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease.
J Med Chem, 59 (22): 10113-10126. [PMID:27933891]
4. Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bassaganya-Riera J. (2018)
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.
Inflamm Bowel Dis, 24 (9): 1978-1991. [PMID:29718324]
5. Leber A, Hontecillas R, Zoccoli-Rodriguez V, Chauhan J, Bassaganya-Riera J. (2019)
Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the Gut.
J Immunol, 202 (7): 2095-2104. [PMID:30760618]